An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
Status:
Terminated
Trial end date:
2019-12-13
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12
(tilavonemab) in participants with progressive supranuclear palsy (PSP).